A Study to Investigate the Efficacy and Safety of Ivonescimab Combined With Irinotecan Liposome as Second-line Regimen for SCLC

Exclusion Criteria

• •1. Patients with other cancer in 5 years.
• •2. Undergone anti-angiogenic therapy prior to the first dose of study treatment.
• •3. Evidence and history of severe bleeding tendency.
• •4. History of severe active autoimmune disease that has required systemic treatment in the past 2 years, severe drug allergy or have known allergy to any component of the study drugs.
• •5. Active central nervous system (CNS) metastases.
• •6. Active infection requiring systemic therapy.
• •7. Current presence of uncontrolled pleural, pericardial, and peritoneal effusions.
• •8. Active hepatitis B/C, or HIV infection.
• •9. History of myocardial infarction, unstable angina, cardiac or other vascular stenting, angioplasty, or surgery within 12 months prior to day 1 of study treatment.
• •10. History of allogeneic hematopoietic stem cell transplantation or allogeneic organ transplantation.
• •11. History of alcohol abuse, psychotropic substance abuse or drug abuse.
• •12. Pregnant or lactating women.
• •13. Other conditions considered unsuitable for this study by the investigator.